AJCN EB Program 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bates, C. J.
Right arrow Articles by Thurnhill, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bates, C. J.
Right arrow Articles by Thurnhill, A.
Agricola
Right arrow Articles by Bates, C. J.
Right arrow Articles by Thurnhill, A.

American Journal of Clinical Nutrition, Vol 50, 825-829, Copyright © 1989 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Riboflavin status of adolescent vs elderly Gambian subjects before and during supplementation

CJ Bates, HJ Powers, R Downes, D Brubacher, V Sutcliffe and A Thurnhill
MRC Dunn Nutrition Unit, Cambridge, UK.

Riboflavin status was measured by activation coefficient of erythrocyte glutathione reductase (EGRAC) in elderly and adolescent rural Gambians whose intakes were low. Fifty-one adolescents and 52 elderly subjects were each subdivided into six supplementation groups to receive 0.25, 0.5, 0.75, 1.0, 1.5, or 2.5 mg riboflavin/d on 5 consecutive days weekly for 5 wk. Before supplementation, EGRAC values were grossly abnormal and differed (p less than 0.005) between the two female groups [elderly subjects, 1.94 +/- 0.33 (means +/- SD); adolescents. 1.72 +/- 0.27] but not between the two male groups. With supplementation greater than 0.25 mg/d the values became nearly equal in the two age groups. Only at total intakes between 1.8 and 2.5 mg riboflavin/d did the subjects attain acceptable status, with a mean EGRAC of 1.3-1.4. Clearly there is a need for further study of the discrepancy between observed index values during supplementation and the accepted ranges of normality at intakes close to the recommended amounts.


This article has been cited by other articles:


Home page
 JPEN J Parenter Enteral NutrHome page
S. Gariballa, S. Forster, and H. Powers
Riboflavin Status in Acutely Ill Patients and Response to Dietary Supplements
JPEN J Parenter Enteral Nutr, November 1, 2009; 33(6): 656 - 661.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
S. Mushtaq, H. Su, M. H. Hill, and H. J Powers
Erythrocyte pyridoxamine phosphate oxidase activity: a potential biomarker of riboflavin status?
Am. J. Clinical Nutrition, November 1, 2009; 90(5): 1151 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
J. R Dainty, N. R Bullock, D. J Hart, A. T Hewson, R. Turner, P. M Finglas, and H. J Powers
Quantification of the bioavailability of riboflavin from foods by use of stable-isotope labels and kinetic modeling
Am. J. Clinical Nutrition, June 1, 2007; 85(6): 1557 - 1564.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
H. J Powers
Riboflavin (vitamin B-2) and health
Am. J. Clinical Nutrition, June 1, 2003; 77(6): 1352 - 1360.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by The American Society for Nutrition